Literature DB >> 22460807

The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.

Isil Z Yildiz-Aktas1, David J Dabbs, Rohit Bhargava.   

Abstract

The American Society of Clinical Oncology/College of American Pathologist (ASCO/CAP) guidelines on breast cancer currently recommend a cold ischemic time of <1 h, although data are limited. Breast resection specimens were subjected to variable cold ischemic time periods (0.5, 1, 2, 3, 4, 24, and 48 h) within the refrigerator and at room temperature. The study included 25 tumors, all of which had refrigerated samples. Non-refrigerated samples (samples at room temperature) were present on 23 cases. Hormone receptors were semi-quantitatively scored using the H-score method. Human epidermal growth factor receptor 2 gene ERBB2 (HER2) was scored using the ASCO/CAP guidelines. The results were compared with the core biopsy scores, which have negligible cold ischemic time period before fixation. Mild reduction in staining for hormone receptors was judged present if the H-score on the resection specimen was between one-half and three-fourth of the H-score at core biopsy. Significant reduction was judged present when the H-score on resection was less than one-half of the core biopsy H-score. Mild reduction in HER2 staining was judged present if there was one-step reduction; and significant reduction was judged present if there was two-step reduction in staining. A true reduction was judged present only when the reduction was consistently present for the increasing time interval. A focal reduction for a particular time sample was attributed to the heterogeneity of the tumor sample. Non-refrigerated samples are affected more by prolonged cold ischemic time than refrigerated samples. Cold ischemic time period of as short as one-half hour may occasionally impact the immunohistochemical (IHC) staining for progesterone receptor. Significant reduction in IHC staining for hormone receptors, and HER2, however, generally does not result until 4 h for refrigerated samples and 2 h for non-refrigerated samples. The ASCO/CAP guideline of cold ischemic time period of <1 h is a prudent guideline to follow.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460807     DOI: 10.1038/modpathol.2012.59

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  38 in total

1.  Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.

Authors:  Bradley M Turner; Kristin A Skinner; Ping Tang; Mary C Jackson; Nyrie Soukiazian; Michelle Shayne; Alissa Huston; Marilyn Ling; David G Hicks
Journal:  Mod Pathol       Date:  2015-05-01       Impact factor: 7.842

Review 2.  Protein biomarkers for subtyping breast cancer and implications for future research.

Authors:  Claudius Mueller; Amanda Haymond; Justin B Davis; Alexa Williams; Virginia Espina
Journal:  Expert Rev Proteomics       Date:  2018-01-03       Impact factor: 3.940

3.  Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue.

Authors:  Bilge Aktas; Hongxia Sun; Hui Yao; Weiwei Shi; Rebekah Hubbard; Ya Zhang; Tingting Jiang; Sophia N Ononye; Vikram B Wali; Lajos Pusztai; W Fraser Symmans; Christos Hatzis
Journal:  Mol Oncol       Date:  2014-02-17       Impact factor: 6.603

Review 4.  Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy.

Authors:  Lokesh Agrawal; Kelly B Engel; Sarah R Greytak; Helen M Moore
Journal:  Semin Cancer Biol       Date:  2017-12-16       Impact factor: 15.707

5.  Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels.

Authors:  Philipp Mertins; Feng Yang; Tao Liu; D R Mani; Vladislav A Petyuk; Michael A Gillette; Karl R Clauser; Jana W Qiao; Marina A Gritsenko; Ronald J Moore; Douglas A Levine; Reid Townsend; Petra Erdmann-Gilmore; Jacqueline E Snider; Sherri R Davies; Kelly V Ruggles; David Fenyo; R Thomas Kitchens; Shunqiang Li; Narciso Olvera; Fanny Dao; Henry Rodriguez; Daniel W Chan; Daniel Liebler; Forest White; Karin D Rodland; Gordon B Mills; Richard D Smith; Amanda G Paulovich; Matthew Ellis; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2014-04-09       Impact factor: 5.911

6.  Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues.

Authors:  Veronique M Neumeister; Valsamo Anagnostou; Summar Siddiqui; Allison Michal England; Elizabeth R Zarrella; Maria Vassilakopoulou; Fabio Parisi; Yuval Kluger; David G Hicks; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2012-10-22       Impact factor: 13.506

7.  Evaluation of three commercial progesterone receptor assays in a single tamoxifen-treated breast cancer cohort.

Authors:  Elizabeth N Kornaga; Alexander C Klimowicz; Natalia Guggisberg; Travis Ogilvie; Don G Morris; Marc Webster; Anthony M Magliocco
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

Review 8.  The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings.

Authors:  Maryam Shabihkhani; Gregory M Lucey; Bowen Wei; Sergey Mareninov; Jerry J Lou; Harry V Vinters; Elyse J Singer; Timothy F Cloughesy; William H Yong
Journal:  Clin Biochem       Date:  2014-01-12       Impact factor: 3.281

9.  HER2 Expression in Gastric Adenocarcinoma-a Study in a Tertiary Care Centre in South India.

Authors:  Raj Aditi; Rau Aarathi; Rudramurthy Pradeep; Lokanatha Hemalatha; C Akshatha; Kumar Amar
Journal:  Indian J Surg Oncol       Date:  2015-07-04

10.  A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort.

Authors:  Elizabeth N Kornaga; Alexander C Klimowicz; Natalia Guggisberg; Travis Ogilvie; Don G Morris; Marc Webster; Anthony M Magliocco
Journal:  Mod Pathol       Date:  2016-04-29       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.